None listed
Conditions
Interventions
Drug : A Randomized, Open-label, 2-Way, 2-Period, Single-Dose Crossover Clinical Study to Compare the Pharmacokinetic Characteristics and the Safety Between Tenelitin Tab and Tenelia Tab in Health ad
Sponsors
Kyung Dong Pharmaceutical
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Healthy male older than 19 to 45 years at the time of screening 2) Body weight more than 50kg and Body Mass Index(BMI) 18~29 kg/m2 ? BMI = (weight [kg])/(height [m])2 3. Subject judged to be eligible by physical examination and interview conducted according to the study protocol. Thus, Subject should not have congenital/chronic disease or pathological symptoms/findings 4. Subject judged to be eligible by clinical tests such as hematology test, blood chemistry test, serum electrolyte test, urine test, Urine Microscopy urine test, serology test performed according to the study protocol 5. Subject who fully understands the clinical trials after in-depth explanation, volunteers to join the clinical trials and signs inform consent
Exclusion criteria
Exclusion criteria: 1) Subject currently with or has a history of cardiovascular , respiratory, hepatic, renal, neurological, endocrine, hemato-oncology, psychiatric, urinary diseases that is clinically significant 2) Subject with a history of significant hypersensitivity or clinically significant hypersensitivity reaction to Tenelitin and other drugs (aspirin, antibiotic…etc.) 3) Systolic blood pressure ?100mmHg or ? 150mmHg, diastolic blood pressure?55mmHg or ? 95mmHg 4) The below patient or condition - Hypopituitarism or adrenal insufficiency - Malnutrition, starvation, irregular eating, lack of meals or weakness - Patients with intense muscle movements 5) A person with a history of abdominal surgery or intestinal obstruction 6) Patients who are prone to QT interval prolongation (patients with severe arrhythmia such as bradycardia or patients with past medical history, patients with heart disease such as congestive heart failure, hypokalemia patients, etc.) 7) Subject with the following results in the clinical laboratory tests - Aspartate Transaminase(AST) or Alanine Transaminase(ALT) > 2 x upper limit of normal range - Total Bilirubin > 2.0 mg/dl - CK > 2 x upper limit of normal range - eGFR < 60 mL/min/1.73m2 8) Subject who takes alcohol > 21 units/week, 1unit=10g=12.5ml of pure alcohol) or can’t stop drinking during the clinical trials 9) Subject who smokes> 10 cigarettes/day or can’t stop smoking during the clinical trials 10) Taking medication involved in other clinical trials within 90 days before the first administration 11) Whole blood donation within 60 days or component blood donation within 30 days before the first administration 12) Taking Prescription drug (ETC) or oriental medicine within two weeks and any OTC within 2 weeks before the first administration 13) Taking metabolizing enzyme inducers or inhibitors such as barbitals within 30 days before the first administration 14) Subject with mental illness or substance abuse 15) Consumption of food which can significantly change the absorption, distribution, metabolism and excretion of a drug within 7 days before the first administration (such as grapefruit or its components) 16)Those who do not agree with the approved method of contraception during the clinical trial 17) Patients judged as inadequate and clinical trials to test self-determined target for any reason. 18) Pregancy, serum/ urine hCG Positive or breasrfeeding female
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Citrulline AUCt , Cmax | — |
Secondary
| Measure | Time frame |
|---|---|
| Citrulline of AUC8, tmax, t1/2, Vd/F, CL/F | — |
Countries
Korea, Republic of
Contacts
Public ContactSang-Heon Cho
Inha University Hospital
Outcome results
None listed